Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL

Linyu Li, Xuhan Zhang, Tingting Zhang, Zheng Song, Ge Hu, Wei Li, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianming Liu, Lixia Feng, Yi Pan, Qiongli Zhai, Bin Meng, Xiubao Ren, Kai Fu, Ping Wang, Xianhuo Wang, Huilai Zhang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We investigated the significance of BCL-2 and BCL-6 expression in MYC+ diffuse large B-cell lymphoma. Immunohistochemistry was performed to evaluate the expression of BCL-2, BCL-6, and MYC. BCL-2 played a more important role than MYC in patients with double-expression lymphoma. Besides, BCL-6 expression might also be a negative prognostic factor for such patients. Background: Double-expression lymphoma (DEL) is a rare subgroup of diffuse large B-cell lymphoma (DLBCL), which has coexpression of MYC and BCL-2. Coexpression of MYC and BCL-2 is considered a prognostic marker portending poor outcomes. However, the prognostic effect of BCL-2 and BCL-6 expression in DLBCL remains controversial. Materials and Methods: Immunohistochemical staining was performed to detect MYC, BCL-2 and BCL-6 expression in 212 patients with newly diagnosed DLBCL and assess the prognostic effects of BCL-2 and BCL-6 expression. The DLBCL patients were treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine [Oncovin], prednisone)–like regimens. Results: Retrospective analysis revealed that BCL-2+ and BCL-2+/MYC+ were prognostic factors indicative of poor outcomes. Patients with BCL-2+ and/or MYC+ expression had a poorer prognosis than that of patients with BCL-2 and/or MYC expression. Patients with BCL-2+/MYC expression showed a trend toward poorer survival than those with BCL-2/MYC+ expression, suggesting that BCL-2 plays a more important role than MYC. Also, patients with BCL-6/MYC+ expression had poorer progression-free survival than those with BCL-6+/MYC+ expression. In addition, patients with BCL-2+/MYC+/BCL-6 expression had the worst prognosis, suggesting that BCL-6 is a prognostic factor for poor outcomes for MYC+ DLBCL patients. Altogether, our findings have shown that BCL-2 is an independent prognostic factor and possibly plays a more important role than MYC in MYC+ DLBCL patients. Furthermore, we found that BCL-6 expression could also be a prognostic factor portending poor outcomes for MYC+ DLBCL patients.

Original languageEnglish (US)
Pages (from-to)e381-e389
JournalClinical Lymphoma, Myeloma and Leukemia
Volume18
Issue number10
DOIs
StatePublished - Oct 2018

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Vincristine
Lymphoma
Prednisone
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Immunohistochemistry

Keywords

  • Clinic
  • Diffuse large B-cell lymphoma
  • Double-expression lymphoma
  • Prognosis
  • Retrospective study

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL. / Li, Linyu; Zhang, Xuhan; Zhang, Tingting; Song, Zheng; Hu, Ge; Li, Wei; Li, Lanfang; Qiu, Lihua; Qian, Zhengzi; Zhou, Shiyong; Liu, Xianming; Feng, Lixia; Pan, Yi; Zhai, Qiongli; Meng, Bin; Ren, Xiubao; Fu, Kai; Wang, Ping; Wang, Xianhuo; Zhang, Huilai.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 18, No. 10, 10.2018, p. e381-e389.

Research output: Contribution to journalArticle

Li, L, Zhang, X, Zhang, T, Song, Z, Hu, G, Li, W, Li, L, Qiu, L, Qian, Z, Zhou, S, Liu, X, Feng, L, Pan, Y, Zhai, Q, Meng, B, Ren, X, Fu, K, Wang, P, Wang, X & Zhang, H 2018, 'Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL', Clinical Lymphoma, Myeloma and Leukemia, vol. 18, no. 10, pp. e381-e389. https://doi.org/10.1016/j.clml.2018.06.010
Li, Linyu ; Zhang, Xuhan ; Zhang, Tingting ; Song, Zheng ; Hu, Ge ; Li, Wei ; Li, Lanfang ; Qiu, Lihua ; Qian, Zhengzi ; Zhou, Shiyong ; Liu, Xianming ; Feng, Lixia ; Pan, Yi ; Zhai, Qiongli ; Meng, Bin ; Ren, Xiubao ; Fu, Kai ; Wang, Ping ; Wang, Xianhuo ; Zhang, Huilai. / Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL. In: Clinical Lymphoma, Myeloma and Leukemia. 2018 ; Vol. 18, No. 10. pp. e381-e389.
@article{f868f2d342994c50b33f86f794309e37,
title = "Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL",
abstract = "We investigated the significance of BCL-2 and BCL-6 expression in MYC+ diffuse large B-cell lymphoma. Immunohistochemistry was performed to evaluate the expression of BCL-2, BCL-6, and MYC. BCL-2 played a more important role than MYC in patients with double-expression lymphoma. Besides, BCL-6− expression might also be a negative prognostic factor for such patients. Background: Double-expression lymphoma (DEL) is a rare subgroup of diffuse large B-cell lymphoma (DLBCL), which has coexpression of MYC and BCL-2. Coexpression of MYC and BCL-2 is considered a prognostic marker portending poor outcomes. However, the prognostic effect of BCL-2 and BCL-6 expression in DLBCL remains controversial. Materials and Methods: Immunohistochemical staining was performed to detect MYC, BCL-2 and BCL-6 expression in 212 patients with newly diagnosed DLBCL and assess the prognostic effects of BCL-2 and BCL-6 expression. The DLBCL patients were treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine [Oncovin], prednisone)–like regimens. Results: Retrospective analysis revealed that BCL-2+ and BCL-2+/MYC+ were prognostic factors indicative of poor outcomes. Patients with BCL-2+ and/or MYC+ expression had a poorer prognosis than that of patients with BCL-2− and/or MYC− expression. Patients with BCL-2+/MYC− expression showed a trend toward poorer survival than those with BCL-2−/MYC+ expression, suggesting that BCL-2 plays a more important role than MYC. Also, patients with BCL-6−/MYC+ expression had poorer progression-free survival than those with BCL-6+/MYC+ expression. In addition, patients with BCL-2+/MYC+/BCL-6− expression had the worst prognosis, suggesting that BCL-6− is a prognostic factor for poor outcomes for MYC+ DLBCL patients. Altogether, our findings have shown that BCL-2 is an independent prognostic factor and possibly plays a more important role than MYC in MYC+ DLBCL patients. Furthermore, we found that BCL-6− expression could also be a prognostic factor portending poor outcomes for MYC+ DLBCL patients.",
keywords = "Clinic, Diffuse large B-cell lymphoma, Double-expression lymphoma, Prognosis, Retrospective study",
author = "Linyu Li and Xuhan Zhang and Tingting Zhang and Zheng Song and Ge Hu and Wei Li and Lanfang Li and Lihua Qiu and Zhengzi Qian and Shiyong Zhou and Xianming Liu and Lixia Feng and Yi Pan and Qiongli Zhai and Bin Meng and Xiubao Ren and Kai Fu and Ping Wang and Xianhuo Wang and Huilai Zhang",
year = "2018",
month = "10",
doi = "10.1016/j.clml.2018.06.010",
language = "English (US)",
volume = "18",
pages = "e381--e389",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "10",

}

TY - JOUR

T1 - Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL

AU - Li, Linyu

AU - Zhang, Xuhan

AU - Zhang, Tingting

AU - Song, Zheng

AU - Hu, Ge

AU - Li, Wei

AU - Li, Lanfang

AU - Qiu, Lihua

AU - Qian, Zhengzi

AU - Zhou, Shiyong

AU - Liu, Xianming

AU - Feng, Lixia

AU - Pan, Yi

AU - Zhai, Qiongli

AU - Meng, Bin

AU - Ren, Xiubao

AU - Fu, Kai

AU - Wang, Ping

AU - Wang, Xianhuo

AU - Zhang, Huilai

PY - 2018/10

Y1 - 2018/10

N2 - We investigated the significance of BCL-2 and BCL-6 expression in MYC+ diffuse large B-cell lymphoma. Immunohistochemistry was performed to evaluate the expression of BCL-2, BCL-6, and MYC. BCL-2 played a more important role than MYC in patients with double-expression lymphoma. Besides, BCL-6− expression might also be a negative prognostic factor for such patients. Background: Double-expression lymphoma (DEL) is a rare subgroup of diffuse large B-cell lymphoma (DLBCL), which has coexpression of MYC and BCL-2. Coexpression of MYC and BCL-2 is considered a prognostic marker portending poor outcomes. However, the prognostic effect of BCL-2 and BCL-6 expression in DLBCL remains controversial. Materials and Methods: Immunohistochemical staining was performed to detect MYC, BCL-2 and BCL-6 expression in 212 patients with newly diagnosed DLBCL and assess the prognostic effects of BCL-2 and BCL-6 expression. The DLBCL patients were treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine [Oncovin], prednisone)–like regimens. Results: Retrospective analysis revealed that BCL-2+ and BCL-2+/MYC+ were prognostic factors indicative of poor outcomes. Patients with BCL-2+ and/or MYC+ expression had a poorer prognosis than that of patients with BCL-2− and/or MYC− expression. Patients with BCL-2+/MYC− expression showed a trend toward poorer survival than those with BCL-2−/MYC+ expression, suggesting that BCL-2 plays a more important role than MYC. Also, patients with BCL-6−/MYC+ expression had poorer progression-free survival than those with BCL-6+/MYC+ expression. In addition, patients with BCL-2+/MYC+/BCL-6− expression had the worst prognosis, suggesting that BCL-6− is a prognostic factor for poor outcomes for MYC+ DLBCL patients. Altogether, our findings have shown that BCL-2 is an independent prognostic factor and possibly plays a more important role than MYC in MYC+ DLBCL patients. Furthermore, we found that BCL-6− expression could also be a prognostic factor portending poor outcomes for MYC+ DLBCL patients.

AB - We investigated the significance of BCL-2 and BCL-6 expression in MYC+ diffuse large B-cell lymphoma. Immunohistochemistry was performed to evaluate the expression of BCL-2, BCL-6, and MYC. BCL-2 played a more important role than MYC in patients with double-expression lymphoma. Besides, BCL-6− expression might also be a negative prognostic factor for such patients. Background: Double-expression lymphoma (DEL) is a rare subgroup of diffuse large B-cell lymphoma (DLBCL), which has coexpression of MYC and BCL-2. Coexpression of MYC and BCL-2 is considered a prognostic marker portending poor outcomes. However, the prognostic effect of BCL-2 and BCL-6 expression in DLBCL remains controversial. Materials and Methods: Immunohistochemical staining was performed to detect MYC, BCL-2 and BCL-6 expression in 212 patients with newly diagnosed DLBCL and assess the prognostic effects of BCL-2 and BCL-6 expression. The DLBCL patients were treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine [Oncovin], prednisone)–like regimens. Results: Retrospective analysis revealed that BCL-2+ and BCL-2+/MYC+ were prognostic factors indicative of poor outcomes. Patients with BCL-2+ and/or MYC+ expression had a poorer prognosis than that of patients with BCL-2− and/or MYC− expression. Patients with BCL-2+/MYC− expression showed a trend toward poorer survival than those with BCL-2−/MYC+ expression, suggesting that BCL-2 plays a more important role than MYC. Also, patients with BCL-6−/MYC+ expression had poorer progression-free survival than those with BCL-6+/MYC+ expression. In addition, patients with BCL-2+/MYC+/BCL-6− expression had the worst prognosis, suggesting that BCL-6− is a prognostic factor for poor outcomes for MYC+ DLBCL patients. Altogether, our findings have shown that BCL-2 is an independent prognostic factor and possibly plays a more important role than MYC in MYC+ DLBCL patients. Furthermore, we found that BCL-6− expression could also be a prognostic factor portending poor outcomes for MYC+ DLBCL patients.

KW - Clinic

KW - Diffuse large B-cell lymphoma

KW - Double-expression lymphoma

KW - Prognosis

KW - Retrospective study

UR - http://www.scopus.com/inward/record.url?scp=85049357373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049357373&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2018.06.010

DO - 10.1016/j.clml.2018.06.010

M3 - Article

C2 - 29983382

AN - SCOPUS:85049357373

VL - 18

SP - e381-e389

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 10

ER -